Celcuity has reported positive Phase 3 clinical trial data for its breast cancer combination therapy, achieving primary endpoints with a significant reduction in mortality risk in certain patient subgroups. The results position Celcuity to pursue FDA approval filings in the fourth quarter, potentially disrupting established treatments from Novartis and Roche. This success underscores the promise of precision oncology in offering improved outcomes and competitive alternatives in HER2-negative breast cancers.